Steven Seedhouse
Stock Analyst at Raymond James
(3.31)
# 972
Out of 4,786 analysts
163
Total ratings
42.41%
Success rate
3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Maintains: Strong Buy | $122 → $125 | $24.15 | +417.60% | 18 | Feb 6, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $1.65 | +1,233.33% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $18.14 | +208.71% | 3 | Nov 8, 2024 | |
| ETNB 89bio | Maintains: Strong Buy | $53 → $49 | $7.27 | +574.00% | 10 | Nov 8, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.33 | +952.63% | 6 | Oct 29, 2024 | |
| KRRO Korro Bio | Initiates: Strong Buy | $153 | $17.41 | +778.81% | 1 | Oct 21, 2024 | |
| WVE Wave Life Sciences | Upgrades: Strong Buy | $13 → $22 | $8.08 | +172.28% | 2 | Oct 16, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $93 | $112.05 | -17.00% | 9 | Jul 8, 2024 | |
| VERA Vera Therapeutics | Maintains: Strong Buy | $57 → $68 | $24.02 | +183.10% | 3 | May 10, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $67 → $106 | $21.87 | +384.68% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $4.91 | +205.50% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $10.46 | +435.37% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $78 → $64 | $45.05 | +42.06% | 18 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.31 | +5,635.82% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $7.11 | +701.69% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $21 → $19 | $1.02 | +1,762.75% | 13 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.29 | +1,605.43% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $1.16 | +1,365.52% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $6.67 | +424.74% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $27.37 | +38.84% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $29.52 | +140.51% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $1.10 | +354.55% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $18.59 | +104.41% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $10.59 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.44 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $136.84 | - | 2 | Apr 23, 2020 |
Viking Therapeutics
Feb 6, 2025
Maintains: Strong Buy
Price Target: $122 → $125
Current: $24.15
Upside: +417.60%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.65
Upside: +1,233.33%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $18.14
Upside: +208.71%
89bio
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $7.27
Upside: +574.00%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.33
Upside: +952.63%
Korro Bio
Oct 21, 2024
Initiates: Strong Buy
Price Target: $153
Current: $17.41
Upside: +778.81%
Wave Life Sciences
Oct 16, 2024
Upgrades: Strong Buy
Price Target: $13 → $22
Current: $8.08
Upside: +172.28%
Gilead Sciences
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $112.05
Upside: -17.00%
Vera Therapeutics
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $24.02
Upside: +183.10%
Apellis Pharmaceuticals
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $21.87
Upside: +384.68%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $4.91
Upside: +205.50%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $10.46
Upside: +435.37%
Dec 19, 2023
Maintains: Strong Buy
Price Target: $78 → $64
Current: $45.05
Upside: +42.06%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.31
Upside: +5,635.82%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $7.11
Upside: +701.69%
Nov 2, 2023
Maintains: Strong Buy
Price Target: $21 → $19
Current: $1.02
Upside: +1,762.75%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.29
Upside: +1,605.43%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $1.16
Upside: +1,365.52%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $6.67
Upside: +424.74%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $27.37
Upside: +38.84%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $29.52
Upside: +140.51%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $1.10
Upside: +354.55%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $18.59
Upside: +104.41%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $10.59
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.44
Upside: -
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $136.84
Upside: -